Drug Search Results
More Filters [+]

Ceftobiprole medocaril

Alternative Names: ceftobiprole medocaril
Latest Update: 2024-04-04
Latest Update Note: News Article

Product Description

a new generation broad-spectrum intravenous cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Ceftobiprole exhibits potent in vitro activity against a number of Gram-positive and Gram-negative pathogens associated with hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25117196/)

Mechanisms of Action: PBP Binder

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Colombia | France

Approved Indications: None

Known Adverse Events: None

Company: Basilea Pharmaceutica
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ceftobiprole medocaril

Countries in Clinic: Argentina, Bulgaria, Colombia, Estonia, Georgia, Germany, Greece, Israel, Italy, Latvia, Lithuania, Mexico, Panama, Poland, Russia, Serbia, Slovakia, South Africa, Spain, Turkey, Ukraine, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Bacteremia|Neonatal Sepsis|Sepsis|Staphylococcal Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BPR-PIP-003

P3

Recruiting

Neonatal Sepsis

2024-12-01

56%

2022-001837-35

P3

Active, not recruiting

Sepsis

2024-02-19

2017-001699-43

P3

Completed

Bacteremia

2022-03-11

BPR-CS-009

P3

Completed

Bacteremia|Staphylococcal Infections

2022-03-11

Recent News Events